Kiniksa Pharmaceuticals (KNSA) Stock Forecast, Price Target & Predictions
KNSA Stock Forecast
Kiniksa Pharmaceuticals stock forecast is as follows: an average price target of $34.00 (represents a 36.38% upside from KNSA’s last price of $24.93) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
KNSA Price Target
The average price target for Kiniksa Pharmaceuticals (KNSA) is $34.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $34.00. This represents a potential 36.38% upside from KNSA's last price of $24.93.
KNSA Analyst Ratings
According to 1 Wall Street analysts, Kiniksa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KNSA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kiniksa Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 03, 2024 | Eva Fortea Verdejo | Wells Fargo | $34.00 | $19.38 | 75.44% | 36.38% |
The latest Kiniksa Pharmaceuticals stock forecast, released on May 03, 2024 by Eva Fortea Verdejo from Wells Fargo, set a price target of $34.00, which represents a 75.44% increase from the stock price at the time of the forecast ($19.38), and a 36.38% increase from KNSA last price ($24.93).
Kiniksa Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $34.00 |
| Last Closing Price | $24.93 | $24.93 | $24.93 |
| Upside/Downside | -100.00% | -100.00% | 36.38% |
In the current month, the average price target of Kiniksa Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kiniksa Pharmaceuticals's last price of $24.93. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 24, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 03, 2024 | Wells Fargo | - | Overweight | Initialise |
Kiniksa Pharmaceuticals's last stock rating was published by Wells Fargo on Jul 24, 2024. The company gave KNSA a "Overweight" rating, the same as its previous rate.
Kiniksa Pharmaceuticals Financial Forecast
Kiniksa Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $67.05M | $71.47M | $48.34M | $61.88M | $99.14M | - | $32.19M | $18.75M | $12.10M | $7.70M | - |
| Avg Forecast | $157.10M | $147.90M | $146.67M | $142.80M | $122.72M | $110.37M | $90.60M | $76.97M | $73.25M | $64.55M | $52.06M | $46.61M | $45.12M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
| High Forecast | $169.37M | $159.45M | $158.12M | $153.95M | $132.30M | $112.01M | $97.68M | $82.98M | $74.13M | $69.60M | $56.13M | $50.25M | $48.64M | $100.88M | $28.42M | $30.79M | $18.00M | $10.49M | $4.39M | $7.95M |
| Low Forecast | $144.42M | $135.96M | $134.83M | $131.27M | $112.81M | $108.73M | $83.29M | $70.76M | $72.38M | $59.34M | $47.86M | $42.85M | $41.47M | $86.02M | $28.42M | $29.52M | $17.26M | $10.06M | $4.21M | $7.62M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 1.37% | 1.04% | 1.37% | 1.06% | - | 1.07% | 1.07% | 1.18% | 1.80% | - |
Kiniksa Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $73.25M, with a low forecast of $72.38M, and a high forecast of $74.13M. KNSA's average Quarter revenue forecast represents a 9.26% increase compared to the company's last Quarter revenue of $67.05M (Sep 23).
Kiniksa Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-10.93M | $-3.15M | $-11.20M | $6.05M | $46.41M | - | $-23.32M | $-35.39M | $-30.00M | $-39.83M | $-48.96M |
| Avg Forecast | $30.13M | $28.37M | $28.13M | $27.39M | $23.54M | $21.17M | $17.38M | $-22.20M | $14.05M | $12.38M | $9.99M | $-23.74M | $8.65M | $-43.67M | $5.45M | $-25.39M | $-26.12M | $-39.70M | $-44.45M | $-48.97M |
| High Forecast | $32.48M | $30.58M | $30.33M | $29.53M | $25.37M | $21.48M | $18.73M | $-17.76M | $14.22M | $13.35M | $10.77M | $-18.99M | $9.33M | $-34.93M | $5.45M | $-20.31M | $-20.89M | $-31.76M | $-35.56M | $-39.18M |
| Low Forecast | $27.70M | $26.08M | $25.86M | $25.18M | $21.64M | $20.85M | $15.97M | $-26.63M | $13.88M | $11.38M | $9.18M | $-28.49M | $7.95M | $-52.40M | $5.45M | $-30.47M | $-31.34M | $-47.64M | $-53.34M | $-58.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.88% | -0.32% | 0.47% | 0.70% | -1.06% | - | 0.92% | 1.35% | 0.76% | 0.90% | 1.00% |
1 analysts predict KNSA's average Quarter EBITDA for Mar 23 to be $-23.74M, with a high of $-18.99M and a low of $-28.49M. This is -492.56% lower than Kiniksa Pharmaceuticals's previous annual EBITDA (Dec 22) of $6.05M.
Kiniksa Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-13.86M | $14.97M | $-12.27M | $4.46M | $224.09M | - | $-25.21M | $-36.33M | $-30.54M | $-41.56M | $-49.48M |
| Avg Forecast | $9.23M | $7.10M | $8.28M | $8.99M | $5.90M | $3.21M | $-5.46M | $-24.73M | $-6.98M | $-11.77M | $-10.06M | $-26.45M | $-14.38M | $-44.45M | $-32.14M | $-28.28M | $-26.82M | $-40.41M | $-46.38M | $-49.48M |
| High Forecast | $10.17M | $7.82M | $9.12M | $9.91M | $6.50M | $22.48M | $-4.89M | $-19.78M | $-2.54M | $-10.54M | $-9.00M | $-21.16M | $-12.87M | $-35.56M | $-32.14M | $-22.63M | $-21.45M | $-32.33M | $-37.11M | $-39.59M |
| Low Forecast | $8.26M | $6.36M | $7.42M | $8.05M | $5.28M | $-19.27M | $-6.01M | $-29.67M | $-11.43M | $-12.97M | $-11.08M | $-31.74M | $-15.84M | $-53.34M | $-32.14M | $-33.94M | $-32.18M | $-48.49M | $-55.66M | $-59.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.18% | -1.49% | 0.46% | -0.31% | -5.04% | - | 0.89% | 1.35% | 0.76% | 0.90% | 1.00% |
Kiniksa Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-11.77M, with a range of $-12.97M to $-10.54M. KNSA's average Quarter net income forecast represents a -178.63% decrease compared to the company's last Quarter net income of $14.97M (Jun 23).
Kiniksa Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $34.47M | $29.18M | $29.05M | $27.21M | $24.68M | - | $22.22M | $22.74M | $20.76M | $21.85M | $20.60M |
| Avg Forecast | $161.93M | $152.44M | $151.17M | $147.19M | $126.49M | $113.76M | $93.38M | $21.79M | $75.51M | $66.54M | $53.66M | $23.31M | $46.50M | $30.21M | $29.29M | $24.93M | $16.79M | $10.57M | $4.42M | $8.01M |
| High Forecast | $174.57M | $164.35M | $162.98M | $158.68M | $136.37M | $115.45M | $100.68M | $26.15M | $76.40M | $71.73M | $57.85M | $27.97M | $50.13M | $36.25M | $29.29M | $29.91M | $20.14M | $10.82M | $4.52M | $8.20M |
| Low Forecast | $148.86M | $140.14M | $138.97M | $135.31M | $116.28M | $112.07M | $85.85M | $17.43M | $74.61M | $61.17M | $49.33M | $18.65M | $42.75M | $24.17M | $29.29M | $19.94M | $13.43M | $10.37M | $4.34M | $7.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.52% | 0.54% | 1.25% | 0.59% | 0.82% | - | 0.89% | 1.35% | 1.96% | 4.94% | 2.57% |
Kiniksa Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $75.51M, based on 3 Wall Street analysts, with a range of $74.61M to $76.40M. The forecast indicates a 119.06% rise compared to KNSA last annual SG&A of $34.47M (Sep 23).
Kiniksa Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.20 | $0.21 | $-0.18 | $0.06 | $3.23 | - | $-0.36 | $-0.53 | $-0.44 | $-0.61 | $-0.72 |
| Avg Forecast | $0.13 | $0.10 | $0.12 | $0.13 | $0.08 | $0.05 | $-0.08 | $-0.08 | $-0.10 | $-0.17 | $-0.14 | $-0.16 | $-0.20 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
| High Forecast | $0.14 | $0.11 | $0.13 | $0.14 | $0.09 | $0.32 | $-0.07 | $-0.07 | $-0.04 | $-0.15 | $-0.13 | $-0.14 | $-0.18 | $0.52 | $-0.46 | $-0.42 | $-0.40 | $-0.63 | $-0.83 | $-0.71 |
| Low Forecast | $0.12 | $0.09 | $0.10 | $0.11 | $0.07 | $-0.27 | $-0.08 | $-0.09 | $-0.16 | $-0.18 | $-0.16 | $-0.18 | $-0.22 | $0.42 | $-0.46 | $-0.44 | $-0.42 | $-0.67 | $-0.87 | $-0.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.21% | -1.48% | 1.13% | -0.30% | 6.82% | - | 0.84% | 1.29% | 0.68% | 0.72% | 0.99% |
According to 1 Wall Street analysts, Kiniksa Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.17, with a low estimate of $-0.18 and a high estimate of $-0.15. This represents a -178.95% decrease compared to KNSA previous annual EPS of $0.21 (Jun 23).
Kiniksa Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.17 | $33.86 | 1460.37% | Buy |
| KRON | Kronos Bio | $0.98 | $7.63 | 678.57% | Buy |
| SPRO | Spero Therapeutics | $1.32 | $10.00 | 657.58% | Buy |
| CHRS | Coherus BioSciences | $1.24 | $9.00 | 625.81% | Hold |
| GOSS | Gossamer Bio | $0.91 | $3.75 | 312.09% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| REPL | Replimune Group | $10.37 | $24.20 | 133.37% | Buy |
| GPCR | Structure Therapeutics | $36.95 | $83.67 | 126.44% | Buy |
| LYRA | Lyra Therapeutics | $0.27 | $0.50 | 85.19% | Hold |
| LRMR | Larimar Therapeutics | $8.05 | $14.50 | 80.12% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| COGT | Cogent Biosciences | $10.47 | $18.50 | 76.70% | Buy |
| BOLT | Bolt Biotherapeutics | $0.65 | $1.00 | 53.85% | Hold |
| KURA | Kura Oncology | $19.29 | $28.67 | 48.63% | Buy |
| PHAT | Phathom Pharmaceuticals | $17.72 | $25.83 | 45.77% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $24.93 | $34.00 | 36.38% | Buy |
| NUVL | Nuvalent | $86.25 | $107.33 | 24.44% | Buy |
| ACLX | Arcellx | $71.25 | $61.00 | -14.39% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
KNSA Forecast FAQ
Is Kiniksa Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Kiniksa Pharmaceuticals (KNSA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of KNSA's total ratings.
What is KNSA's price target?
Kiniksa Pharmaceuticals (KNSA) average price target is $34 with a range of $34 to $34, implying a 36.38% from its last price of $24.93. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kiniksa Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for KNSA stock, the company can go up by 36.38% (from the last price of $24.93 to the average price target of $34), up by 36.38% based on the highest stock price target, and up by 36.38% based on the lowest stock price target.
Can Kiniksa Pharmaceuticals stock reach $40?
KNSA's average twelve months analyst stock price target of $34 does not support the claim that Kiniksa Pharmaceuticals can reach $40 in the near future.
What are Kiniksa Pharmaceuticals's analysts' financial forecasts?
Kiniksa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $400.66M (high $424.97M, low $375.59M), average EBITDA is $39.89M (high $47.83M, low $31.83M), average net income is $-21.071M (high $4.31M, low $-49.67M), average SG&A $355.43M (high $378.64M, low $331.63M), and average EPS is $-0.0306 (high $0.266, low $-0.372). KNSA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $594.47M (high $640.89M, low $546.48M), average EBITDA is $114.01M (high $122.92M, low $104.81M), average net income is $33.61M (high $37.02M, low $30.08M), average SG&A $612.74M (high $660.59M, low $563.27M), and average EPS is $0.473 (high $0.521, low $0.424).
Did the KNSA's actual financial results beat the analysts' financial forecasts?
Based on Kiniksa Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $270.26M, beating the average analysts forecast of $236.48M by 14.28%. Apple's EBITDA was $-25.196M, missing the average prediction of $12.68M by -298.74%. The company's net income was $-47.388M, missing the average estimation of $-55.262M by -14.25%. Apple's SG&A was $129.43M, missing the average forecast of $219.01M by -40.90%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-0.565 by -99.88%. In terms of the last quarterly report (Sep 2023), Kiniksa Pharmaceuticals's revenue was $67.05M, beating the average analysts' forecast of $64.55M by 3.86%. The company's EBITDA was $-10.927M, missing the average prediction of $12.38M by -188.26%. Kiniksa Pharmaceuticals's net income was $-13.855M, beating the average estimation of $-11.772M by 17.70%. The company's SG&A was $34.47M, missing the average forecast of $66.54M by -48.20%. Lastly, the company's EPS was $-0.2, beating the average prediction of $-0.166 by 20.63%